China’s Veterinary Drug Market Set to Hit 920B RMB by 2026: Key Trends in Pet Pharma, Antibiotic Reduction, and Industry Consolidation

Here’s a number worth sitting with: 920 billion RMB. That’s where China’s veterinary drug market is headed by 2026, up from 621 billion in 2020 and 850 billion last year. But the top-line growth hides a more interesting story underneath. The industry is being reshaped by three things that don’t always get discussed in the same breath — the pet boom, the antibiotic clampdown, and the slow consolidation of farms into industrial-scale operations.

This isn’t your father’s animal health business anymore.

Three Ways to Look at This Market

The veterinary drug market isn’t one market. It’s several, layered on top of each other. How you see it depends on how you slice it.

By drug type. Chemical drugs are still the workhorses — broad-spectrum antibiotics, antiparasitics, common disinfectants. They move in massive volumes at thin margins. Biological products like vaccines and diagnostic kits are the opposite: fewer units, higher prices, much steeper technical barriers. Traditional Chinese veterinary medicines sit somewhere in between — smaller share, steady demand, valued for safety more than potency.

By target animal. Livestock and poultry soak up most of the volume. Aquaculture is its own beast — dosing through feed or directly into water creates residue problems that regulators are watching closely. Pet pharmaceuticals are the outlier. Higher margins, closer to human drug standards, growing faster than anything else in the sector.

By administration route. Oral formulations dominate because you can dose an entire barn through the drinking water. Injectables work faster and cost more, but you need someone who knows what they’re doing. Topicals are a small but growing niche, mainly in the pet market where convenience matters.

These three perspectives overlap in ways that make the market feel oddly fragmented. No one company dominates. Competition looks completely different depending on which corner of the market you’re standing in.

The Policy Shift Nobody Missed

The old playbook was simple: more farms, more antibiotics, more revenue. That playbook stopped working a while ago.

Dual licensing is a real hurdle. Every manufacturer needs both a production license and a product approval number. Both have gotten harder to get over the past few years. The compliance burden for new entrants keeps going up.

The antibiotic reduction push is serious. China set a target: by end of 2025, half of all large-scale farms should have cut antibiotic use, and residue pass rates need to stay above 98%. If your product portfolio leans heavily on traditional antibiotics, that’s a problem. If you’ve got alternatives in the pipeline — probiotics, enzyme-based products, herbal feed additives — it’s an opportunity.

Pet drug reform actually happened. For a long time, pet owners in China had to make do with livestock drugs used off-label. The regulatory pipeline for pet-specific products was essentially clogged. That changed starting around 2020, when the government simplified the pathway for converting approved human drugs to pet use. A 2022 update extended the same logic to traditional Chinese medicines. Clinical trial requirements got trimmed for certain categories. The result: a wave of new pet drug applications that would have been unthinkable a few years ago.

QR code tracking is now mandatory. Every package of veterinary drugs sold in China has to be traceable through the supply chain — manufacturing, wholesale, retail, online. For small manufacturers, this is a huge operational headache. For the industry as a whole, it’s the kind of infrastructure that actually builds trust.

The “Three Reductions, One Optimization” reform. Mid-2025 brought a streamlining of the drug review process. Fewer review pathways, simpler documentation, clearer timelines. Faster approvals for innovators. Shorter windows for copycats.

Who Makes the Stuff

As of late 2025, China had 1,781 GMP-certified veterinary drug manufacturers. The geography tells you something: 302 in Shandong, 207 in Henan, 135 in Shanxi, 127 in Jiangsu, 124 in Hebei. These are the country’s major farming and chemical production regions. The factories sit where the farms are.

The product breakdown is lopsided. Chemical drug manufacturers account for 1,354 of those 1,781 facilities — 76% of the total. TCVM producers number 610, though most of them also make chemical drugs. Vaccine producers are the boutique segment: 110 facilities, higher margins, higher barriers. Diagnostic kit makers number about 129.

What caught my attention: only about two-fifths of API producers also make finished formulations. Vertical integration is still rare. That means most manufacturers are exposed to raw material price swings they can’t control.

Three Problems That Won’t Fix Themselves

Let’s not sugarcoat it. This industry has real structural problems.

Product homogeneity. Walk through any veterinary drug expo in China and you’ll see the same products under different brand names. Most companies run on copycat formulations. The result is a price war that kills margins and starves R&D budgets. It’s a low-equilibrium trap, and it’s hard to climb out of.

Poor capacity utilization. A lot of factories run at 50% or less. The fixed costs of GMP-compliant facilities don’t go down just because you’re not using them. So companies face an ugly choice: run full and destroy pricing, or run half and bleed cash.

Quality inconsistencies. When margins are squeezed, something has to give. Some manufacturers use cheaper raw materials, skip quality checks, or cut corners on process steps. The result is batch-to-batch variation that affects clinical outcomes and creates food safety risks downstream.

Where Things Are Heading

Consolidation is coming. The model of 1,800 manufacturers all competing in the same space won’t hold. Higher compliance costs — GMP upgrades, digital tracking, quality systems — all favor larger players. Companies with proper R&D pipelines and distribution networks will absorb the rest.

The research-to-commercialization gap is narrowing. For years, veterinary drug innovation in China lived in university labs. Companies and academics didn’t talk much. That’s changing. More firms are setting up joint labs with research institutes. Some leading players are building end-to-end pipelines from discovery to market. Multi-valent vaccines and combination products are starting to emerge.

Green chemistry is becoming a differentiator. Low-residue, fast-degrading, environmentally cleaner formulations are shifting from nice-to-have to table stakes. Regulators are looking at both products and production processes. Companies that get ahead of this will have a real advantage.

Pet pharma is the growth story nobody predicted at this scale. Pet ownership in China has exploded over the past decade. Veterinary care followed, but the drug supply lagged. Now that the regulatory door is open and consumers are willing to spend, pet-specific pharmaceuticals are the most attractive growth segment in the entire industry.

Export is on the radar. Chinese manufacturers have historically sold mostly domestically. That’s starting to change. A few Tier-1 companies are looking at Southeast Asia, Africa, and Latin America. The challenges are real — registration, distribution, brand building — but the pull of overseas margins is getting harder to ignore.

So What

China’s veterinary drug market has moved past the easy growth phase. The next stage belongs to companies that can handle regulatory complexity, invest in actual R&D, and build brands that mean something to both farmers and pet owners. For everyone else, the squeeze will only get tighter. The shakeout is here. It started a while ago.